Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.36 |
| ▸ | NPY1R | P25929 | 9/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.36 |
| ▸ | NPY2R | P49146 | 5/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9614574 | 0.95 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL25413181 | 0.89 | DPP7 (0.39) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL2183420 | 0.87 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL1521188 | 0.87 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL1521191 | 0.87 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL6436667 | 0.87 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL28719983 | 0.87 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL11012210 | 0.87 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL4087611 | 0.87 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL10724867 | 0.86 | DPP7 (0.40) | NPY4RNPY1RNPY5RNPY2RDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050260275-A1 | Encapsulated peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| CN-1617881-A | Chemical process | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050260275-A1 | Encapsulated peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, CTRC | NPY4R 496/4885NPY1R 170/4885NPY5R 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.